Effects of Oxytocin and Carbetocin on Renal System in Cesarean Sections

Ufuk University

Status: Unknown

Conditions: Postpartum Hemorrhage

Treatments: Drug: Carbetocin; Drug: Oxytocin

Study type: Observational

Funder types: Other

Identifiers

NCT03939806

CO2019

Details and patient eligibility

About

The aim of this study is to evaluate the renal outcome of patients undergoing elective C/S where oxytocin or carbetocin is used for postpartum hemorrhage prophylaxis.

Enrollment: 100 estimated patients

Sex: Female

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Term (>37 weeks of gestation) uncomplicated pregnant women undergoing elective cesarean section

Exclusion criteria

• Patients refusing to participate in the study
• Complicated pregnancies
• Patients with risk factors for postpartum hemorrhage
• Contraindications for oxytocin or carbetocin usage
• Patients with known renal diseases
• Preterm births (<37 weeks of gestation)

Trial design

100 participants in 2 patient groups

Oxytocin

Description:

This group will be given 3 IU / 3 ml oxytocin (intravenously) after the clamping of the umbilical cord. Uterine tonus will be assessed after 60 seconds and if it is lower than 7, oxytocin 3 IU / 3 ml will be repeated, up to a maximum of three times. If uterine tonus is still lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.

Treatment:

Drug: Oxytocin

Carbetocin

Description:

This group will be given 100 mcg / 3 ml carbetocin (intravenously) after the clamping of the umbilical cord. If uterine tonus is lower than 7, rescue uterotonics such as intramuscular methylergonovine or intravenous misoprostol will be administered.

Treatment:

Drug: Carbetocin